History and Prospect of Vaccines Against Pertussis
Advances in Bioscience and Bioengineering
Volume 7, Issue 1, March 2019, Pages: 8-12
Received: Jun. 9, 2019; Accepted: Jul. 4, 2019; Published: Jul. 16, 2019
Views 528      Downloads 122
Authors
Kaminaka Kazuyoshi, Development Department, KM Biologics Co., Ltd., Kumamoto, Japan
Chikateru Nozaki, Department of Medical Technology, Kumamoto Health Science University, Kumamoto, Japan
Article Tools
Follow on us
Abstract
Pertussis, known as whooping cough, is a severe respiratory disease most commonly caused by the bacterium Bordetella pertussis. It is transmitted from person to person by aerosols and infects the ciliated epithelium of the airways. Pertussis was responsible for high mortality rates before the introduction of effective vaccines in the second half of the 20th century. Vaccination is thought to be the most effective method for control pertussis. There have been two types of pertussis vaccines available. The first-generation vaccine was the whole-cell vaccine, which was efficacious. However, it caused occasional side effects. The whole-cell vaccine was gradually replaced by the acellular vaccine. The acellular vaccine consists of detoxified, purified pertussis antigens. Despite the widespread use of the acellular vaccine, pertussis has recently been on the rise. In order to overcome such a situation, developments of new pertussis vaccines are in progress over the world. One is a genetically modified live vaccine which is thought to maintain safety while inducing immunity close to natural infection. And also there are a mucosal vaccine using lactic acid bacteria carrying components of pertussis and a bacterium-like particle vaccine with components of pertussis. In this review we introduce history and prospect of vaccines against pertussis.
Keywords
Pertussis, Whole-Cell Vaccine, Acellular Vaccine, Live Attenuated Vaccine, Lactococcus lactis, Bacterium-like Particle
To cite this article
Kaminaka Kazuyoshi, Chikateru Nozaki, History and Prospect of Vaccines Against Pertussis, Advances in Bioscience and Bioengineering. Vol. 7, No. 1, 2019, pp. 8-12. doi: 10.11648/j.abb.20190701.12
Copyright
Copyright © 2019 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
References
[1]
Kilgore PE, Salim AM, Zervos MJ, Schmitt HJ. Pertussis: Microbiology, Disease, Treatment, and Prevention. Clin Microbiol Rev. 2016 29 (3): 449-86.
[2]
G. Fedele, P. Stefanelli, Pertussis in infants and the resurgence of a vaccine preventable disease: what to do? Commentary, Ann. Istituto. Super. Sanita 53 (2) (2017 Apr-Jun) 100–103.
[3]
Mattoo S, Cherry JD. Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies. Clin Microbiol Rev. 2005; 18 (2): 326–382.
[4]
Pertussis vaccines: WHO position paper - September 2015. Wkly Epidemiol Rec. 2015; 90 (35): 433–458.
[5]
Falleiros Arlant LH, de Colsa A, Flores D, Brea J, Avila Aguero ML, Hozbor DF. Pertussis in Latin America: epidemiology and control strategies. Expert Rev Anti Infect Ther. 2014; 12 (10): 1265–1275.
[6]
Mazzilli S, Tavoschi L, Lopalco PL. Tdap vaccination during pregnancy to protect newborns from pertussis infection. Ann Ig. 2018 Jul-Aug; 30 (4): 346-363.
[7]
Delma J. Nieves, Ulrich Heininger. 2016. Bordetella pertussis. Microbiol Spectr. 2016 Jun; 4 (3).
[8]
Versteegh F, Schellekens J, Fleer A, Roord J. Pertussis: a concise historical review including diagnosis, incidence, clinical manifestations and the role of treatment and vaccination in management. Rev Med Microbiol 2005; 16: 79–89. [Google Scholar].
[9]
Mattoo S, Cherry JD. Review Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies. Clin Microbiol Rev. 2005 Apr; 18 (2): 326-82.
[10]
Trollfors B. Bordetella pertussis whole cell vaccines--efficacy and toxicity. Acta Paediatr Scand. 1984 Jul; 73 (4): 417-25.
[11]
Edwards KM1, Karzon DT. Pertussis vaccines. Pediatr Clin North Am. 1990 Jun; 37 (3): 549-66.
[12]
Wintermeyer SM1, Nahata MC, Kyllonen KS. Whole-cell and acellular pertussis vaccines. Ann Pharmacother. 1994 Jul-Aug; 28 (7-8): 925-39.
[13]
Sato Y, Sato H. Development of acellular pertussis vaccines. Biologicals. 1999 Jun; 27 (2): 61-9.
[14]
Campins-Martí M1, Moraga-Llop FA. Acellular pertussis vaccines for use among infants and young children. Expert Opin Pharmacother. 2004 Apr; 5 (4): 807-17.
[15]
Bailey J. Acellular vaccines for preventing pertussis in children. Am Fam Physician. 2011 Sep 1; 84 (5): 504.
[16]
Brummelman J, Wilk MM, Han WG, van Els CA, Mills KH. Roads to the development of improved pertussis vaccines paved by immunology. Pathog Dis. 2015 Nov; 73 (8).
[17]
Mazzilli S, Tavoschi L, Lopalco PL. Tdap vaccination during pregnancy to protect newborns from pertussis infection. Ann Ig. 2018 Jul-Aug; 30 (4): 346-363.
[18]
Patterson J, Kagina BM, Gold M, Hussey GD, Muloiwa R. Comparison of adverse events following immunisation with acellular and whole-cell pertussis vaccines: A systematic review. Vaccine. 2018 Sep 25; 36 (40): 6007-6016.
[19]
von König CH, Halperin S, Riffelmann M, Guiso N. (2002) Pertussis of adults and infants. Lancet Infect Dis 2: 744–750.
[20]
Wirsing von König CH, Postels-Multani S, Bock HL, Schmitt HJ (1995) Pertussis in adults: Frequency of transmission after household exposure. Lancet 346: 1326–1329.
[21]
Mielcarek N, Debrie AS, Raze D, Bertout J, Rouanet C, et al. (2006) Live attenuated B. pertussis as a single-dose nasal vaccine against whooping cough. PLoS Pathog 2: e65.
[22]
Feunou PF, Kammoun H, Debrie AS, Mielcarek N, Locht C. Long-term immunity against pertussis induced by a single nasal administration of live attenuated B. pertussis. Vaccine. 2010 Oct 8; 28 (43): 7047-53.
[23]
Li R, Lim A, Alonso S. Attenuated Bordetella pertussis BPZE1 as a live vehicle for heterologous vaccine antigens delivery through the nasal route. Bioeng Bugs. 2011 Nov-Dec; 2 (6): 315-9.
[24]
Thorstensson R, Trollfors B, Al-Tawil N, Jahnmatz M, Bergström J, Ljungman M, Törner A, Wehlin L, Van Broekhoven A, Bosman F, Debrie AS, Mielcarek N, Locht C. A phase I clinical study of a live attenuated Bordetella pertussis vaccine--BPZE1; a single centre, double-blind, placebo-controlled, dose-escalating study of BPZE1 given intranasally to healthy adult male volunteers. PLoS One. 2014 Jan 8; 9 (1): e83449.
[25]
Higgs R, Higgins SC, Ross PJ, Mills KH. Immunity to the respiratory pathogen Bordetella pertussis. Mucosal Immunol. 5 (5) (2012 Sep) 485–500.
[26]
Ross PJ, Sutton CE, Higgins S, Allen AC, Walsh K, Misiak A, Lavelle EC, McLoughlin RM, Mills KH. Relative contribution of Th1 and Th17 cells in adaptive immunity to Bordetella pertussis: towards the rational design of an improved acellular pertussis vaccine, PLoS Pathog. 9 (4) (2013) e1003264.
[27]
Hellwig SM, van Spriel AB, Schellekens JF, Mooi FR, van de Winkel JG. Immunoglobulin A-mediated protection against Bordetella pertussis infection. Infect. Immun. 69 (8) (2001 Aug) 4846–4850 PubMed PMID: 11447159.
[28]
Bermúdez-Humarán LG. Lactococcus lactis as a live vector for mucosal delivery of therapeutic proteins. Hum. Vaccine 5 (4) (2009 Apr) 264–267.
[29]
Pontes DS, de Azevedo MS, Chatel JM, Langella P, Azevedo V, Miyoshi A. Lactococcus lactis as a live vector: heterologous protein production and DNA delivery systems. Protein Expr. Purif. 79 (2) (2011 Oct) 165–175.
[30]
Isaka M, Yasuda Y, Taniguchi T, Kozuka S, Matano K, Maeyama J, Morokuma K, Ohkuma K, Goto N, Tochikubo K. Mucosal and systemic antibody responses against an acellular pertussis vaccine in mice after intranasal co-administration with recombinant cholera toxin B subunit as an adjuvant. Vaccine 21 (11–12) (2003) 1165–1173.
[31]
Asokanathan C, Corbel M, Xing D. A CpG-containing oligodeoxynucleotide adjuvant for acellular pertussis vaccine improves the protective response against Bordetella pertussis. Hum. Vaccines Immuno therapeutics 9 (2) (2014) 325–331.
[32]
van Roosmalen ML, Kanninga R, El Khattabi M, Neef J, Audouy S, Bosma T, Kuipers A, Post E, Steen A, Kok J, Buist G, Kuipers OP, Robillard G, Leenhouts K. Mucosal vaccine delivery of antigens tightly bound to an adjuvant particle made from food-grade bacteria, Methods 38 (2) (2006) 144–149.
[33]
Yeh CY, Yeh TH, Jung CJ, Chen PL, Lien HT, Chia JS. Activated imumannasal epithelial cells modulate specific antibody response against bacterial or viral antigens, PLoS One 8 (2) (2013) e55472.
[34]
Van Braeckel-Budimir N, Haijema BJ, Leenhouts K. Bacterium-like particles for efficient immune stimulation of existing vaccines and new subunit vaccines in mucosal applications. Front. Immunol. 4 (2013) 282.
[35]
Lu J, Hou H, Wang D, Leenhouts K, Roosmalen MLV, Sun T, Gu T, Song Y, Jiang C, Kong W, Wu Y. Systemic and mucosal immune responses elicited by intranasal immunization with a pneumococcal bacterium-like particle-based vaccine displaying pneumolysin mutant Plym2. Immunol. Lett. 187 (2017) 41–46.
[36]
Ramirez K, Ditamo Y, Rodriguez L, Picking WL, van Roosmalen ML, Leenhouts K, Pasetti MF. Neonatal mucosal immunization with a non-living, non-genetically modified Lactococcus lactis vaccine carrier induces systemic and local Th1-type immunity and protects against lethal bacterial infection. Mucosal Immunol. 3 (2) (2010) 159–171.
[37]
Ramasamy R, Yasawardena S, Zomer A, Venema G, Kok J, Leenhouts K. Immunogenicity of a malaria parasite antigen displayed by Lactococcus lactis in oral immunisations. Vaccine 24 (18) (2006) 3900–3908.
[38]
Audouy SA, van Roosmalen ML, Neef J, Kanninga R, Post E, van Deemter M, Metselaar H, van Selm S, Robillard GT, Leenhouts KJ, Hermans PW. Lactococcus lactis GEM particles displaying pneumococcal antigens induce local and systemic immune responses following intranasal immunization. Vaccine 24 (26) (2006) 5434–5441.
ADDRESS
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
U.S.A.
Tel: (001)347-983-5186